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Mucopolysaccharidosis type I (MPS I; McKusick 25280; Hurler syndrome, Hurler–Scheie syndrome and Scheie syndrome) is caused by
a deficiency in the lysosomal hydrolase, a-L-iduronidase (EC 3.2.1.76). MPS I patients present within a clinical spectrum bounded by the
extremes of Hurler and Scheie syndromes. The a-L-iduronidase missense mutations R89Q and R89W were investigated and altered an
important arginine residue proposed to be a nucleophile activator in the catalytic mechanism of a-L-iduronidase. The R89Q a-L-iduronidase
mutation was shown to result in a reduced level of a-L-iduronidase protein (V 10% of normal control) compared to a normal control level of
a-L-iduronidase protein that was detected for the R89W a-L-iduronidase mutation. When taking into account a-L-iduronidase specific
activity, the R89W mutation had a greater effect on a-L-iduronidase activity than the R89Q mutation. However, overall the R89W mutation
produced more residual a-L-iduronidase activity than the R89Q mutation. This was consistent with MPS I patients, with an R89W allele,
having a less severe clinical presentation compared to MPS I patients with either a double or single allelic R89Q mutation. The effects of the
R89Q and R89W mutations on enzyme activity supported the proposed role of R89 as a nucleophile activator in the catalytic mechanism of
a-L-iduronidase.
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Mucopolysaccharidosis type I (MPS I; Hurler syndrome;
Scheie syndrome; McKusick 25280) is a lysosomal storage
disorder that is caused by a deficiency in the lysosomal acid
hydrolase, a-L-iduronidase (EC 3.2.1.76). a-L-Iduronidase
specifically cleaves iduronic acid residues from the nonre-
ducing terminus of the long-chain polysaccharides derived
from the proteoglycans, dermatan sulfate and heparan sul-
fate. An a-L-iduronidase deficiency causes the blockage of
further sequential degradation of these polysaccharides and
results in the lysosomal accumulation and urinary excretion
of the partially degraded substrates. MPS I patients show a
wide spectrum of clinical presentations ranging from the0925-4439/$ - see front matter. Crown Copyright D 2003 Published by Elsevier
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called Scheie syndrome, where a few patients approach a
near-normal clinical presentation [1].
Patients at the severe end of the clinical spectrum present
with hydrocephalus, coarse facial features, corneal clouding,
enlarged tongue, hepatosplenomegaly, hernia, cardiac dis-
ease, short stature, dysostosis multiplex, joint stiffness,
clawed hands, fatigue and delay of mental development
[1]. In this severe form of the disorder, the onset of the
disease is rapid and progressive, with patients often suffer-
ing an early death before the teenage years. Scheie syn-
drome patients typically display variable clinical symptoms
that can include coarse facial features, corneal clouding,
cardiac valve disease, joint stiffness, clawed hands, malaise/
fatigue and other somatic features. The onset of these
clinical symptoms is usually delayed compared to that in
Hurler syndrome patients and the disease progression is less
rapid. In some patients with an attenuated form of the
disorder, intelligence can be normal, stature can be relatively
normal and the patient can have a normal lifespan.B.V. All rights reserved.
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identified in the a-L-iduronidase gene (IDUA) causing
MPS I [2–6]. MPS I is an autosomal recessively inherited
disorder, with most patients presenting as compound heter-
ozygotes for the IDUA disease alleles. The two premature
stop codon mutations W402X and Q70X are the most
common IDUA mutations in Caucasians, being responsible
for up to 70% of the disease alleles in some countries
[2,3,7–9]. The W402X and Q70X mutations both produce
no detectable a-L-iduronidase protein in MPS I patient
fibroblasts [7,8,10] and, in the homozygous condition, result
in a very severe clinical presentation. The P533R mutation
has been reported to be a common mutation with a partic-
ularly high frequency of detection in Sicilian Italian and
Moroccan MPS I patients [11,12]. MPS I patients with a
P533R/P533R genotype present with, at most, a slightly
attenuated clinical phenotype when compared to classical
Hurler syndrome patients [12,13]. In Japanese MPS I
patients the R89Q mutation [14] is one of the most common
mutant alleles and is associated with an attenuated clinical
phenotype in patients with a R89Q/R89Q genotype [4]. This
arginine residue at position 89 of a-L-iduronidase has been
proposed to be a key residue in the catalytic mechanism for
a-L-iduronidase [15,16].
Here MPS I patients with either a R89Q or a R89W
mutation have been described and had an attenuated clinical
phenotype. The R89Q and R89W mutations have been
expressed in Chinese hamster ovary (CHO-K1) cells to
facilitate analysis of the biosynthesis, processing, traffic
and biochemistry of the mutant a-L-iduronidase protein.
The findings were consistent with the R89Q and R89W a-
L-iduronidase mutations altering a key residue in the cata-
lytic mechanism of a-L-iduronidase. Differences in the
severity of clinical presentation, for MPS I patients with
the two different mutations, were explained by a balance of
the effect for each mutation on the enzyme activity and
structure/stability of the a-L-iduronidase protein.2. Materials and methods
2.1. Materials
The wild-type human IDUA cDNA was previously de-
scribed [17]. Plasmid pcDNA3.1(+) was from Invitrogen
(CH Groningen, The Netherlands). Oligonucleotides for mu-
tagenesis and sequencing were purchased from Life Tech-
nologies/Gibco BRLR (Rockville, MD). ABI PRISMR
dGTP BigDyek Terminator v3.0 Ready Reaction Cycle
Sequencing Kit was purchased from Applied Biosystems
(Foster City, CA). Polyvinylchloride plates (96 well, ELISA
plates) were obtained from Costar (Corning Life Sciences,
Acton, MA). Pansorbin cells (507861) and the a-L-iduroni-
dase substrate, 4-methylumbelliferyl a-L-iduronide (MUI;
fluorogenic substrate) were from Calbiochem (Croydon,
Australia). Amplify and nitrocellulose membrane were pur-chased from Amersham Biosciences (Castle Hill, Australia).
Ovalbumin, bovine serum albumin (BSA), G418 and tri-
chloroacetic acid (TCA) were purchased from Sigma (Castle
Hill, Australia). Sheep anti-mouse immunoglobulin (SAM-
Ig) and horse-radish peroxidase-conjugated sheep anti-rabbit
immunoglobulin were purchased from Silenus Laboratories
(a subsidiary of Chemicon, Temecula, CA). Foetal calf serum
(FCS) for tissue culture, L-glutamine and Dulbecco’s Modi-
fied Eagle’s Medium/Ham’s Nutrient Mixture F-12 (Coon’s
Modified) were from JRH Biosciences (Lenexa, KS). 35S-
Methionine radiolabel was purchased from NENk Life
Science Products (Boston, MA).
2.2. Site-directed mutagenesis for R89W
A 2155-bp fragment encoding the wild-type human
IDUA cDNA [17] was subcloned into pcDNA3.1(+) at
the EcoRI restriction site and the resulting construct was
used for the generation of the R89W mutant using a
QuikChangek Site-Directed Mutagenesis kit (Stratagene,
La Jolla, CA). The mutant oligonucleotides used for the
construction of the R89W mutant were (sense) 5V-
GGCATCAAGCAGGTCTGGACCCACTGGCTGCTGG-
3V and (antisense) 5V-CCAGCAGCCAGTGGGTCCA -
GACCTGCTTGATGCC-3V. Both mutant fragments were
verified by DNA sequence analysis, using the ABI PRISMR
dGTP BigDyek Terminator v3.0 Ready Reaction Cycle
Sequencing Kit. Large-scale plasmid stocks were prepared
using a QIAGEN Plasmid Midi Kit (Qiagen, Clifton Hill,
Australia).
2.3. Generation of CHO-K1 clones expressing R89W
human IDUA protein
Ten micrograms of pcDNA3.1R89W was electroporated
into CHO-K1 cells as previously described [18] and trans-
fected colonies selected following growth in the presence of
0.75 mg/ml G418. G418-resistant mass cultures were main-
tained in G418 medium for 2 weeks. The cell line was then
cloned and rescreened for G418 resistance. The control cell
line expressing wild-type human a-L-iduronidase has been
previously reported [19].
2.4. Generation of the R89Q mutation and transfection into
CHO-K1 cells
Total RNA was isolated from patient cells containing the
R89Q mutation and PCR performed using the high-fidelity
thermostable DNA polymerase tet-z to generate a 333-bp
product containing the mutation [14]. This fragment was
directionally cloned into the corresponding region of the
wild-type clone pRSVN.ID [17]. Mutations were con-
firmed by direct DNA sequencing. CHO-K1 cells were
then transfected with the mutant construct using 5-Ag
plasmid DNA and the DOTAP reagent according to the
manufacturer’s protocol (Roche Applied Science, Castle
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mass culture.
2.5. Cell culture
CHO-K1 cells were grown in Dulbecco’s Modified
Eagle’s Medium/Ham’s Nutrient Mixture F-12 (Coon’s
Modified) supplemented with 10% (v/v) FCS. The culture
media from confluent 75-cm2 flasks were collected and
clarified by centrifugation at 400 g for 10 min prior to
being stored sterile at 4 jC. The cell layers were washed
twice with 10 ml of Dulbeccos’s phosphate-buffered saline
(PBS) prior to incubation with 10% (v/v) trypsin–versene
solution, for 2 min at 37 jC, to release the cells for
harvesting. After centrifugation (400 g for 5 min) the cell
pellet from the harvested cells was washed with PBS and re-
centrifuged. The supernatant was removed and the cell
pellet was then used for either organelle fractionation or
cell extract preparation for further analysis.
2.6. Preparation of cell extracts and cell protein assays
Confluent CHO-K1 cells were harvested as described
above and a cell pellet produced. For direct IDUA activity,
immunoquantification, immunobinding assays and Western
blot analysis, each cell pellet was resuspended in 200 Al of
20 mM Tris/HCl pH 7.0 containing 0.5 M NaCl, then
freeze/thawed six times. The samples were then centrifuged
at 10,000 g for 5 min and the supernatant taken and stored
at  20 jC. The total amount of protein in the cell lysates
was determined by the method of Lowry [20].
2.7. Enzyme kinetics
The Km, Vmax and catalytic efficiency of human a-L-
iduronidase mutations were determined in human fibroblast
cell lines as previously described [9,10]. Briefly, confluent
75-cm2 flasks of human a-L-iduronidase mutant fibroblast
cell lines were harvested and assayed for IDUA activity
[9,10] using a-L-iduronosyl [1,4] anhydromannitol-6-sulfa-
te3H (IMS) as the substrate. IMS was prepared as previously
described [21]. Reaction mixtures were analysed by sepa-
ration on cation exchange high performance liquid chroma-
tography with on-line scintillation detection. From the
IDUA activities established for various substrate concen-
trations, Michaelis–Menten kinetics was ascertained. Line-
weaver–Burk plots and linear-regression analysis were used
to establish Km and Vmax results. Catalytic efficiency was
calculated by Vmax/Km.
2.8. Direct a-L-iduronidase activity assay
Total a-L-iduronidase activity in the cell lysates and
media samples was determined in a direct assay employing
a fluorogenic substrate, 4-methylumbelliferyl a-L-iduronide,
as previously described [22,23].2.9. Immunobinding assay
An immune capture method was used to specifically bind
human a-L-iduronidase protein, followed by a 4-methylum-
belliferyl a-L-iduronide assay to determine a-L-iduronidase
enzyme activity as previously described [24]. Briefly, 100
Al of affinity purified sheep anti-mouse immunoglobulin (20
Ag/ml in 0.1 M NaHCO3 pH 8.5) was attached to each well
of a 96-well polyvinylchloride plate (ELISA plate) by
overnight incubation at 4 jC. The plate was then washed
with 0.02 M Tris/HCl, pH 7.0, containing 0.25 M NaCl on a
plate washer to remove unbound antibody. One-hundred
microliters of ID1A monoclonal antibody culture superna-
tant was adsorbed to the sheep anti-mouse immunoglobulin
on the plate by incubation for 4 h at 20 jC. The plate was
then rewashed and blocked (to reduce reactive sites on the
plate and nonspecific binding) by incubating each well with
200 Al of 0.02 M Tris/HCl, pH 7.0, containing 0.25 M NaCl
and 1% (w/v) ovalbumin, for 1 h at 20 jC. Dilutions of a-L-
iduronidase (CHO-K1 expression culture media) of known
activity were prepared for a standard curve. For a-L-idur-
onidase activity determination, dilutions of the cell extracts
and culture media were then incubated (100 Al/well) for 16
h at 4 jC. The plate was then rewashed, as above, to remove
unbound sample and non-a-L-iduronidase protein. Wells
were then assayed for a-L-iduronidase activity by incubation
with 30 Al of 4-methylumbelliferyl a-L-iduronide substrate
(0.5 mM), containing 0.067 M sodium dimethylglutarate,
pH 4.5 and 2.3 mg/ml BSA in 0.3% (w/v) NaCl, for 4 h at
37 jC. Reactions were stopped by the addition of 1.6 ml of
0.2 M glycine/0.125 M Na2CO3 pH 10.7. Enzyme activity
was detected on a luminescence spectrofluorimeter (Perkin
Elmer LS50B, Rowville, Australia) by measuring the fluo-
rescence due to the release of 4-methylumbelliferone at 446
nm, using an excitation wavelength of 366 nm. Results were
interpolated through a standard curve and enzyme activity
expressed as nmol/min/ml of sample or nmol/min/mg after
correcting for cellular protein levels.
2.10. Immunoquantification assay
a-L-Iduronidase polypeptide levels were measured by an
immunoquantification assay, as previously described [10]. A
polyclonal antibody to a-L-iduronidase was used to capture
the protein prior to detection with the monoclonal antibody
ID1A and a peroxidase-labelled secondary antibody. Results
were corrected either for total cell protein levels or volume
of media samples.
2.11. Western blot analysis
Cell lysates (60 Ag) and media samples (110 Ag) were
electrophoresed on 10% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS PAGE) using standard
conditions [25]. The gel was transferred to nitrocellulose
and immunoblotted as previously described [26]. Briefly,
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NaCl/20 mM Tris pH 7 for 1 h before incubating with a
specific polyclonal antibody against human a-L-iduronidase
(1:100 dilution of serum in 1% (w/v) BSA in 0.25 M NaCl/
20 mM Tris pH 7) for 16 h at 4 jC with rocking. After
washing the immunoblot with 0.25 M NaCl/0.02 M Tris pH
7, horse-radish peroxidase-conjugated sheep anti-rabbit im-
munoglobulin was used as a secondary antibody (1:1000
dilution). Detection was achieved using 0.5 mg/ml 4-chloro-
1-naphthol and H2O2 (3.3 Al per 10 ml of substrate) in 0.02
M Tris/HCl pH 7 containing 0.25 M NaCl.
2.12. Organelle fractionation of CHO-K1 cells
CHO-K1 cells were harvested and a granular fraction
prepared for organelle subfractionation on an 18% (v/v)
Percoll gradient as previously described [27]. Briefly, cells
were harvested as described above and the cell pellet
resuspended in 10 mM HEPES pH 7.0 containing 0.25
M sucrose, 1 mM ethylenediamine tetra-acetic acid and
protease inhibitors. The cell suspension was then subjected
to hypobaric shock, prior to centrifugation at 400 g for
10 min at 4 jC to remove cellular debris. The post-nuclear
supernatant produced was then subfractionated on an 18%
(v/v) Percoll gradient, by centrifugation at 31,400 g for 1
h at 4 jC. Twenty 1-ml fractions were collected from the
top to the bottom of the gradient. Each fraction was
assayed for h-hexosaminidase and acid phosphatase activ-
ity as previously described [28], using the fluorogenic
substrates 4-methylumbelliferyl-N-acetyl-h-D-glucosami-
nide and 4-methylumbelliferyl-phosphate, respectively
[29,30]. The salt concentration of each fraction was
adjusted to 0.25 M and then freeze/thawed six times before
centrifugation at 100,000 g for 1 h at 4 jC to remove the
Percoll and cell membranes. A 200 Al aliquot of the
supernatant of each fraction was precipitated using deox-
ycholate/TCA as previously described [31] in order to
decrease the sample volume and salt content prior to
running on a 10% SDS PAGE and immunoblotting as
described above. Each fraction across the gradient was also
assayed for a-L-iduronidase activity using the capture
assay described above.
2.13. Pulse chase labelling
Confluent 75 cm2 tissue culture flasks of CHO-K1 cells
were preincubated for 45 min in cysteine/methionine-free
Dulbecco’s Modified Eagle’s Medium containing 10% (v/
v) FCS and 2 mM glutamine, before labelling with 0.49
mCi of 35S-methionine for 30 min at 37 jC in 5 ml of the
same culture medium. The radiolabelled media was aspi-
rated and the cells washed twice with 10 ml of PBS before
either harvesting (pulse label) or adding 8 ml of Hams-F12
containing 10% (v/v) FCS for chase times of either 4, 24
or 48 h. Culture medium was then collected from each
flask and centrifuged at 400 g for 5 min and storedsterile at 4 jC prior to immunoprecipitation and the CHO-
K1 cell layers harvested. The cell pellets were resuspended
in 10 ml of solubilisation buffer [PBS containing 1% (w/v)
Na deoxycholate, 0.1% (w/v) SDS, 0.5% (v/v) Triton
X100].
2.14. Immunoprecipitation
Radiolabelled cell extracts and media samples were
immunoprecipitated using antibody attached to pansorbin
cells (i.e. source of protein A). Pansorbin cells were
equilibrated by washing four times with solubilisation
buffer (3000 g for 2 min at 4 jC). Cell extracts and
media samples were pre-cleared by three incubation steps.
Samples were first incubated with 60 Al of equilibrated
pansorbin cells for 2 h at 4 jC, with constant mixing. After
centrifugation at 3000 g for 5 min at 4 jC, the superna-
tant was collected and incubated with 60 Al of sheep anti-
mouse immunoglobulin (SAM-Ig)-bound pansorbin cells
(15 Ag of SAM-Ig per 60 Al of pansorbin cells) for 2 h at
4 jC. After further centrifugation the supernatant was
incubated with 60 Al of rabbit serum bound pansorbin cells
(15 Al rabbit serum per 60 Al pansorbin cells) for 2 h at 4
jC. Five milliliters of ID1A monoclonal culture supernatant
(approximately 10 Ag/ml monoclonal antibody) was bound
to an additional 1.3 ml of pansorbin–SAM-Ig (by incuba-
tion at 4 jC for 2 h, with mixing), washed with solubilisa-
tion buffer and centrifuged as above to remove any
unbound monoclonal antibody. Sixty microliters of the
pansorbin–SAM-Ig–ID1A complex was incubated with
the cell extracts/culture medium, overnight at 4 jC with
mixing. The pansorbin complex was pelleted by centrifu-
gation at 3000 g for 5 min prior to three 1-ml washes
with solubilisation buffer, and finally one wash with 0.5-ml
water. The pansorbin complex was then resuspended in
SDS-PAGE sample buffer, containing 5% (v/v) h-mercap-
toethanol, and boiled for 5 min. The pansorbin cells were
pelleted at 3000 g for 5 min and the supernatant was
loaded onto a 10% polyacrylamide gel and electrophoresed
as described above. The gel was fixed in 40% (v/v)
methanol/10% (v/v) acetic acid for 1 h, prior to placing
in Amplify solution overnight at 20 jC and subsequent
autoradiographic detection of radiolabelled a-L-iduronidase.3. Results
3.1. MPS I patients with either R89Q or R89W mutant
a-L-iduronidase
Two MPS I patients have been detected with an R89W
a-L-iduronidase mutant allele. One patient had a Q70X/
R89W genotype [9] while the other, reported here, had a
P533R/R89W genotype (Table 1). Both of these patients had
an attenuated clinical phenotype (Table 1). The Q70X allele
has been previously associated with a very severe clinical
Table 1
MPS I patient biochemical and clinical phenotype parameters
Genotype Mutant protein
(ng/mg)
Km Vmax Catalytic efficiency,
Vmax/Km
Clinical presentation
W402X/W402X
Q70X/Q70X
ND
ND
ND
ND
ND
ND
0.0
0.0
Hydrocephalus, coarse face,
corneal clouding, enlarged tongue,
hepatosplenomegaly, hernia,
cardiac disease, short stature,
dysostosis multiplex, joint stiffness,
clawed hands, fatigue, mental delay,
early death.a
W402X/P533R
P533R/P533R
0.33 114 0.4 0.0035 Coarse face, corneal clouding,
hepatosplenomegaly, hernia,
cardiac disease, short stature,
dysostosis multiplex, and mental delay.b
W402X/R89Q
R89Q/R89Q
0.4–2.0 65 0.45 0.0069 Corneal clouding, hepatosplenomegaly,
cardiac disease, slightly short stature,
dysostosis multiplex, joint stiffness.c
P533R/R89W
Q70X/R89Wd
24
149
216
114
3.4
4.6
0.0157
0.040
Borderline short stature, hernia,
slight hepatosplenomegaly,
slight vertebral changes, cardiac disease,
joint stiffness.
Normal 17–54 6–34 288–517 9.3–82.0 Normal
ND, not detectable. The kinetic data for normal controls was representative of determinations for 7 individuals.
a Clinical description of Hurler syndrome [1].
b Observations on MPS I patients with P533R mutations [11–13].
c Observations on MPS I patients with R89Q mutations [4].
d Protein and kinetic data for this patient have been previously published [9].
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single P533R, when present with a severe allelic mutation,
has been shown to result in a relatively minor attenuation of
clinical presentation compared to classical Hurler syndrome
[8]. The presence of an R89W allele in two MPS I patients
with an attenuated clinical presentation suggested that this
mutation resulted in some residual a-L-iduronidase protein
and activity. Both MPS I patients with an R89W allele had
either normal or higher-than-normal levels of a-L-iduroni-
dase protein in fibroblast cell extracts (Table 1). In contrast,Table 2
R89Q, R89W and R89 CHO-K1 expression cell lines
Total cell
protein
(mg/ml)
a-L-Iduronidase
protein (Ag/mg)
a-L
acti
assa
(nm
Cell extracts
CHO-K1 10.2 ND 3.2
R89 CHO-K1 8.2 31.8 361
R89W CHO-K1 6.3 28.3 53.
R89Q CHO-K1 6.5 2.9 Not
Media
CHO-K1 – ND 0.3
R89 CHO-K1 – 2.5 17.
R89W CHO-K1 – 2.4 8.8
R89Q CHO-K1 – 0.02 Not
ND, not detectable. a-L-Iduronidase protein and activity in CHO-K1 cells expressin
activity results are expressed per milligram of total cell protein for cell extracts athe mutation R89Q, involving the same a-L-iduronidase
residue, resulted in only low levels of a-L-iduronidase
protein in patient fibroblast extracts (Table 1). Despite the
lower level of a-L-iduronidase protein, MPS I patients with
an R89Q mutation displayed an attenuated clinical pheno-
type. Enzyme kinetic analysis of fibroblast cell extracts from
MPS I patients with an R89Q a-L-iduronidase mutation
showed a slightly elevated Km and a low Vmax, consistent
with altered ability to degrade substrate (Table 1). Enzyme
kinetic analysis of fibroblast cell extracts from MPS I-Iduronidase
vity direct
y (n= 4)
ol/min/mg)
a-L-Iduronidase
activity captured
(n= 3)
(nmol/min/mg)
Total a-L-iduronidase
activity captured
(total nmol/min)
F 0.7 ND ND
.9F 38.3 384.5F 34.2 628.2F 55.9
6F 3.3 37.3F 4.3 46.8F 5.4
done 15.7F 1.7 28.1F 3.3
F 0.1 ND ND
5F 2.3 18.3F 1.1 219.1F12.9
F 1.8 2.4F 0.3 29.3F 3.0
done 0.01F 0.002 0.1F 0.02
g wild-type, R89Wand R89Q a-L-iduronidase. a-L-Iduronidase protein and
nd per milliliter for media samples.
Fig. 1. Immunoblot of human wild-type and mutant a-L-iduronidase
expressed in CHO-K1 cells and secreted into the cell culture media. Lanes
1–3 show the banding pattern for cell culture media from CHO-K1 cells
expressing R89W (lane 1), wild-type (lane 2) and untransfected CHO-K1
cells (lane 3). Lanes 4–6 show the banding pattern for cell extracts from
CHO-K1 cells expressing R89W (lane 4), wild-type (lane 5) and
untransfected CHO-K1 cells (lane 6). The a-L-iduronidase protein was
detected using a polyclonal antibody and peroxidase labelled secondary
antibody. The molecular mass of the a-L-iduronidase species present was
determined from pre-stained molecular weight markers (BenchMarkk
Prestained Protein Ladder, Invitrogen) and was indicated on the figure with
arrows.
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showed a high Km and low Vmax (Table 1). These results
were consistent with a tendency for the R89W mutation to
alter a-L-iduronidase enzyme activity but not protein struc-
ture/stability, while the R89Q mutation had an effect on both
protein structure/stability and enzyme activity. The clinical
phenotype for MPS I patients with an R89W a-L-iduronidaseFig. 2. Graph of a-L iduronidase activity detected in organelles of wild-type
fractionation. One-milliliter fractions were collected from the top to the bottom of
protein. Each fraction across the gradient was assayed for a-L-iduronidase activity
wild type (n) and pmol/min/ml for R89W (o) and R89Q (D) CHO-K1 expressmutation was less severe when compared to patients that
were either homo-allelic or hetero-allelic for the R89Q
mutation (Table 1).
3.2. R89Q and R89W a-L-iduronidase protein expression in
CHO-K1 cells
The R89Q and R89W a-L-iduronidase mutations were
expressed in CHO-K1 cells for protein and cell biological
analysis (Table 2). R89Q a-L-iduronidase CHO-K1 expres-
sion cells only produced V 10% of the level of a-L-
iduronidase protein in cell extracts when compared to
wild-type R89 a-L-iduronidase CHO-K1 cells. In cell
culture medium (secreted form) the R89Q a-L-iduronidase
protein was V 1% of that detected for the R89 a-L-
iduronidase CHO-K1 cell control. In contrast, R89W a-
L-iduronidase CHO-K1 expression cells produced a similar
level of a-L-iduronidase protein in both cell extracts
(intracellular) and cell culture media (secreted) when
compared to wild-type R89 a-L-iduronidase CHO-K1 cells.
Although the latter two expression systems were produced
using different promoters, there was no detectable differ-
ence between expression of wild-type R89 a-L-iduronidase
in either system (unpublished observations). Immunoblot
analysis also showed similar levels of mutant R89W and
R89 a-L-iduronidase protein in cell extracts and culture
media from the respective expression cell lines (Fig. 1).
The R89Q mutation resulted in a lower level of intracel-
lular a-L-iduronidase protein when compared to the R89W
mutation (Table 2).and mutant a-L-iduronidase CHO-K1 expression cells after subcellular
the Percoll gradient, prior to freeze/thawing to release the a-L-iduronidase
using the immune capture assay. Results were expressed in nmol/min/ml for
ion cells.
Fig. 4. Pulse chase and immunoprecipitation of human wild-type and
R89W mutant a-L-iduronidase expressed in CHO-K1 cells. Pulse radio-
labelled CHO-K1 cells were either harvested at time 0 or chased for 4, 24 or
48 h (as indicated on the figure) prior to immunoprecipitation and
visualisation on an SDS PAGE for autoradiographic detection. Cell extracts
(a) were from untransfected (lanes 1–4), wild-type (lanes 5–8) or R89W
(lanes 9–12) CHO-K1 cells. Culture media (b) were from untransfected
(lanes 1–3), wild-type (lanes 4–6) or R89W (lanes 7–9) CHO-K1 cells.
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The R89Q CHO-K1 cells produced a level of human a-L-
iduronidase activity that was less than 5% of that detected in
normal control R89 CHO-K1 expression cells (Table 2).
This was less than the level of activity expected for the a-L-
iduronidase protein detected in these cells by a factor of 2.
The R89W CHO-K1 cells produced approximately 10% of
the level of human a-L-iduronidase activity detected in
normal control R89 CHO-K1 expression cells. This repre-
sented a 10-fold reduction in enzyme activity when com-
pared to the level of a-L-iduronidase protein detected (i.e.
normal or greater than normal a-L-iduronidase protein for
R89W compared to R89). This suggested that the substitu-
tion of an arginine (basic side chain) residue at position 89
in a-L-iduronidase with a glutamine (uncharged polar side
chain) was a more conservative change for a-L-iduronidase
activity when compared to the substitution with a trypto-
phan (nonpolar side chain) residue. The reverse was true for
protein structure/stability. The total amount of a-L-iduroni-
dase activity distributed to the intracellular pool was three-
fold higher than that detected in the secreted pool for wild
type R89 CHO-K1 cells. In contrast, the R89W was 1.5-fold
higher, suggesting some selective inactivation of the intra-
cellular compared to the secreted pool of R89W a-L-idur-
onidase. The substantial reduction in R89Q a-L-iduronidase
activity in the secreted pool was mainly due to the lack of
mutant a-L-iduronidase protein secreted from the R89Q
CHO-K1 expression cells.
3.4. Subcellular distribution and protein processing of
R89Q and R89W a-L-iduronidase
Granular fractionation of CHO-K1 cells expressing either
R89 (wild type), R89Q or R89W a-L-iduronidase demon-
strated that the majority of a-L-iduronidase was distributedFig. 3. Subcellular distribution of molecular forms of wild-type (a) and
R89W (b) mutant a-L-iduronidase expressed in CHO-K1 cells were
visualised on Western blots after preparing postnuclear supernatants and
then subfractionating on 18% Percoll gradients. One-milliliter fractions
were collected from the top to the bottom of the gradient and then freeze/
thawed to release the a-L-iduronidase protein. Two-hundred microliters of
the supernatant was TCA protein precipitated to decrease sample volume
and salt content, before running on a 10% SDS PAGE and immunoblotting.
The a-L-iduronidase protein was detected using a polyclonal antibody and
peroxidase-labelled secondary antibody.to high density organelles characteristic of lysosomes (Figs.
2 and 3). The mutant R89Q and mutant R89W a-L-idur-
onidase were distributed in Percoll gradients with a similar
pattern to that detected for wild-type R89 a-L-iduronidase
(Fig. 2), which in turn was coincident with h-hexosamini-
dase activity (data for the latter not shown). The levels of a-
L-iduronidase activity detected in organelles from R89Q and
R89W CHO-K1 cells were approximately 5% and 10%
(respectively) of that detected in the R89 CHO-K1 cells
(Fig. 2). This was consistent with the a-L-iduronidase
activities detected in the total cell extracts from these
expression cells (Table 2).
Immunoblot analysis of cell extracts demonstrated a
similar pattern of a-L-iduronidase polypeptide processing
at steady state in R89W CHO-K1 cells compared to the R89
CHO-K1 cells (wild-type control) (Fig. 1). The reduced
level of a-L-iduronidase protein detected in the R89Q CHO-
K1 cells made immunoblot detection impractical (data not
shown). Pulse labelling and chase experiments on R89W
cells indicated a similar pattern of a-L-iduronidase process-
ing for R89 and R89W CHO-K1 cells, but with some
evidence of delayed rate of secretion for the mutant
R89W a-L-iduronidase (Fig. 4).4. Discussion
The large number of a-L-iduronidase mutations identified
in MPS I patients are thought to be a major factor for the
heterogeneity of clinical presentation in this disorder. MPS I
patients have previously been classified according to three
recognised clinical phenotypes: severe Hurler syndrome,
intermediate Hurler-Scheie syndrome and mild Scheie syn-
drome [1]. In reality, there is a spectrum of possible MPS I
clinical presentations ranging from the severe classical
Hurler syndrome to the attenuated Scheie syndrome, with
L.K. Hein et al. / Biochimica et Biophysica Acta 1639 (2003) 95–103102many intermediate subtly different clinical phenotypes. A
relatively large number of MPS I patients have deletion
mutations, which result in a very severe clinical presenta-
tion, and this has been well characterised [2,3,32]. The
mutant alleles that result in attenuated MPS I clinical
presentations have been less well characterised. Here we
have investigated two mutations affecting the same a-L-
iduronidase residue (R89), which results in different clinical
presentations, but with both tending towards the attenuated
end of the MPS I clinical spectrum.
The a-L-iduronidase mutation R89Q has been described
as a common mutation with a high frequency of detection in
Japanese MPS I patients [4]. Thus far, the a-L-iduronidase
mutation R89W has been detected in two unrelated MPS I
patients [9]. This arginine residue is rigidly conserved
amongst glycosidases. The R89 residue in a-L-iduronidase
has been postulated to be involved in the catalytic mecha-
nism of a-L-iduronidase as a nucleophile activator [15,16].
Mutation of this key residue would be expected to result in a
substantial but possibly not a complete loss of a-L-iduroni-
dase catalytic activity.
The arginine-to-tryptophan substitution (R89W) was
structurally conservative, as it resulted in a normal level
of a-L-iduronidase protein in CHO expression cells and was
consistent with the level of protein detected in MPS I
patients with an R89W allele. The main effect of the
R89W mutation was on enzyme activity, with the nonpolar
tryptophan substitution resulting in a 10-fold reduction in
a-L-iduronidase specific activity, when compared to the R89
control. This indicated that the R89 residue was required for
efficient substrate turnover, but that it was not an absolute
requirement for a-L-iduronidase catalytic activity. In con-
trast, the introduction of a polar glutamine residue into a-L-
iduronidase (R89Q) resulted in reduced mutant a-L-iduro-
nidase protein levels (10-fold lower) but resulted in this
residual protein having only slightly reduced specific ac-
tivity (twofold lower) when compared to the R89 a-L-
iduronidase control. This suggested that the primary effect
of the R89Q mutation was on protein structure and/or
stability, with the substituted polar glutamine still making
a contribution to substrate catalysis. Overall, the R89Q
mutation had more impact on the residual level of a-L-
iduronidase activity (20-fold reduction) than the R89W
mutation (10-fold reduction), when compared to the R89
a-L-iduronidase wild-type control.
The biochemical and clinical phenotypes of MPS I
patients with R89Q and R89W mutations were both con-
sistent with the findings from the CHO-K1 expression cell
line studies. In order of clinical severity, MPS I patients with
a single R89Q mutation (when present with a null allele)
[14] had a more severe clinical presentation than patients
with an R89Q/R89Q genotype [4], which in turn was more
severe than the MPS I patients with an R89W allele [9].
Protein analysis showed a normal or higher-than-normal
level of a-L-iduronidase protein in the MPS I patients with
an R89W mutant allele compared to V 10% of a-L-idur-onidase protein for the MPS I patients with an R89Q mutant
allele. Enzyme kinetic analysis showed a marked reduction
in Vmax for the MPS I patients with either an R89W or an
R89Q mutation, although this was more significant for the
R89Q mutation.
In conclusion, the findings here were consistent with the
proposed role of the R89 residue as a nucleophile activator
in the catalytic mechanism of a-L-iduronidase [15,16],
showing that this residue was not absolutely essential for
a-L-iduronidase activity. Previous studies identified E182
and E299 as two critical active site residues in a-L-idur-
onidase (acid/base catalyst and nucleophile, respectively)
[15,16,24,33]. Mutation of the R89 residue had variable
effects on protein structure based on the amino acid intro-
duced, with the introduction of a uncharged polar residue
(R89Q) having more effect on protein structure/stability
compared to the nonpolar tryptophan (R89W). Either an
R89W or an R89Q mutation would tend to generate enough
residual catalytic activity to attenuate the severity of MPS I
clinical presentation away from the severe end of the
clinical spectrum. However, an MPS I patient with an
R89W a-L-iduronidase mutation would be expected to have
a less severe clinical phenotype, compared to an MPS I
patient that was either homozygous or heterozygous for an
R89Q a-L-iduronidase mutation.Acknowledgements
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